Back to top
more

EDAP TMS (EDAP)

(Delayed Data from NSDQ)

$4.89 USD

4.89
1,230

+0.06 (1.18%)

Updated Jul 30, 2024 12:34 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 42% (105 out of 251)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

EDAP TMS S.A. (EDAP) Stock Jumps 18.8%: Will It Continue to Soar?

by Zacks Equity Research

EDAP TMS S.A. (EDAP) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

ViewRay (VRAY) Catches Eye: Stock Jumps 7%

by Zacks Equity Research

ViewRay (VRAY) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

EDAP TMS' Shares March Higher, Can It Continue?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor in EDAP TMS.

EDAP's Shares March Higher, Can It Continue?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor EDAP TMS.

EDAP TMS (EDAP) Catches Eye: Stock Jumps 7.4%

by Zacks Equity Research

EDAP TMS (EDAP) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

EDAP TMS S.A. (EDAP) Moves to Buy: Rationale Behind the Upgrade

by Zacks Equity Research

EDAP TMS S.A. (EDAP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Will EDAP TMS Continue to Surge Higher?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor EDAP TMS.

Top Ranked Momentum Stocks to Buy for September 20th

by Zacks Equity Research

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, September 20th

EDAP TMS S.A. (EDAP) Shares March Higher, Can It Continue?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor in EDAP TMS S.A. (EDAP).

EDAP TMS S.A. (EDAP) Upgraded to Strong Buy: Here's Why

by Zacks Equity Research

EDAP TMS S.A. (EDAP) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

EDAP TMS (EDAP) Looks Good: Stock Adds 7.9% in Session

by Zacks Equity Research

EDAP TMS (EDAP) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

Masimo (MASI) Introduces SafetyNet System in Dubai Hospitals

by Zacks Equity Research

Masimo's (MASI) proprietary Patient SafetyNet system's introduction in the Dubai market is in line with its strategy of becoming the dominant player in the pulse oximetry market.

    athenahealth (ATHN) Shares Rally on Earnings Beat in Q2

    by Zacks Equity Research

    Solid expansion across athenahealth's (ATHN) ambulatory, hospital and population health platforms is expected to provide a competitive edge in the niche RCM space.

      Intuitive Surgical (ISRG) Beats on Q2 Earnings & Revenues

      by Zacks Equity Research

      Intuitive Surgical posted solid numbers in the quarter under review, courtesy of rising customer adoption of procedures and growth in system placements.

        AngioDynamics (ANGO) Shares Down Despite Q4 Earnings Beat

        by Zacks Equity Research

        AngioDynamics (ANGO) revenues declined year over year in the fourth quarter. Recall of the Acculis product line under the oncology segment is also a concern.

          Stryker Poised on Solid Product Portfolio and Acquisitions

          by Zacks Equity Research

          On Jul 17, we issued an updated research report on Kalamazoo, MI-based Stryker Corporation (SYK), one of the largest medical device companies in the global orthopedic market.

            Accuray's Q4 Preliminary Results Fail to Cheer Investors

            by Zacks Equity Research

            Accuray (ARAY) announced its preliminary results for for the fourth quarter and fiscal 2017. Following the announcement, the company's stock lost over 2% in the last trading session to close at $4.70.

              Accuray's Medical Systems to be Acquired by Dubai Hospital

              by Zacks Equity Research

              Accuray Inc. (ARAY) recently announced that it has signed an agreement with the Neuro Spinal Hospital in Dubai, United Arab Emirates.

                DENTSPLY SIRONA Strong on Deal Renewals, Forex Woes Stay

                by Zacks Equity Research

                On Jul 12, we issued an updated research report on NY-based DENTSPLY SIRONA Inc. (XRAY) -- a global leader in the design, development, manufacture and marketing of dental consumables and dental laboratory products.

                  McKesson (MCK) Poised on Improving Generic and Brand Market

                  by Zacks Equity Research

                  On Jul 12, we issued an updated research report on San Francisco, CA-based McKesson Corporation (MCK).

                    Masimo (MASI) Rainbow Super DCI-mini Sensor Now CE Marked

                    by Zacks Equity Research

                    Irvine, CA-based Masimo Corporation (MASI) recently announced the receipt of CE mark for the noninvasive and reusable rainbow Super DCI-mini sensor.

                      Fresenius Medical (FMS) Well Poised on Growth Strategy 2020

                      by Zacks Equity Research

                      On Jul 11, we issued an updated research report on Bad Homburg, Germany-based Fresenius Medical Care (FMS), one of the largest integrated providers of products and services for individuals undergoing dialysis following chronic kidney failure.

                        Becton, Dickinson (BDX) Poised on C.R. Bard Acquisition

                        by Zacks Equity Research

                        On Jul 7, we issued an updated research report on Franklin Lakes, NJ-based Becton, Dickinson and Company (BDX).

                          Mazor Expects Higher Q2 Revenues, Wins Mazor X Orders

                          by Zacks Equity Research

                          Mazor Robotics Ltd. (MZOR), recently announced that it expects to report second-quarter 2017 revenue of approximately $15.4 million compared with $8.3 million from the year-ago quarter.

                            Envision Healthcare Rallies on Infinity Healthcare Buyout

                            by Zacks Equity Research

                            Envision Healthcare Corporation (EVHC) recently announced that Envision Physician Services has acquired Infinity Healthcare, a multi-specialty physician group practice.